This preprint describes the CAUSAL-RSV protocol, designed to estimate the real-world effectiveness of the maternal prefusion F protein subunit vaccine (RSVpreF) against severe infant respiratory syncytial virus (RSV) outcomes when both maternal vaccination and infant prophylactic monoclonal antibodies (mAbs) are available in routine practice. The authors note that 2023 saw US licensure and recommendations for two prevention products: RSVpreF administered during pregnancy and a long-acting infant mAb. While early post-licensure studies support RSVpreF effectiveness in settings where only maternal vaccination was available, the effectiveness of maternal vaccination within a context where infant mAbs are also offered remains unclear. CAUSAL-RSV aims to quantify the total vaccine effect when used as a component of a hybrid prevention program.
CAUSAL-RSV will use a national cohort of mother–infant dyads drawn from the Optum Labs Data Warehouse (OLDW). The analysis will follow dyads longitudinally across multiple RSV seasons. The preprint reports that the cohort will span the 2023–24, 2024–25, and 2025–26 RSV seasons. The abstract does not provide further granular details about inclusion or exclusion criteria, sample size, or specific demographic characteristics of the cohort; those details were not reported in the source abstract.
The central analytic approach is causal mediation analysis that treats receipt of infant long-acting mAb prophylaxis as a mediating variable in the causal pathway between maternal RSVpreF vaccination and severe infant RSV outcomes. The protocol intends to model both vaccine and mAb effects within a longitudinal framework to estimate the total effect of maternal vaccination when infant mAbs may also be administered. The preprint emphasizes applying causal methods to observational real-world data to separate direct and mediated effects, but specific modeling choices, assumptions, variable definitions, confounder control strategies, or statistical estimands were not detailed in the abstract and thus are not reported here.
The stated timeframe for the planned analyses is the three consecutive RSV seasons 2023–24 through 2025–26. The primary outcome of interest, as described in the abstract, is severe infant RSV. The preprint does not define the clinical or administrative coding definitions for “severe” RSV, nor does it report outcome incidence, time windows for follow-up, or secondary endpoints in the abstract; those specifics were not provided in the source material.
The protocol underwent institutional review: the Institutional Review Board of the University of California Los Angeles determined the protocol did not constitute research with human subjects as defined by DHHS and FDA regulations (IRB-25-2622), and therefore IRB review and approval were not required. The authors state that relevant ethical guidelines were followed and that patient/participant consent and data protections were managed as appropriate. The preprint format is noted, and the authors explicitly state the manuscript has not been peer reviewed and should not be used to guide clinical practice pending evaluation.
Funding for the project is reported from the National Institute of Allergy and Infectious Diseases (NIAID), grant R21AI191038. Several authors disclosed potential competing interests: membership on data safety monitoring boards, consulting relationships, and prior investigator roles with multiple vaccine manufacturers and other organizations. Specific disclosures were provided for named authors; the abstract indicates other authors did not report potential conflicts.
The preprint is a protocol/analysis plan rather than a report of empirical results. It frames the contribution as methodological and programmatic: applying causal mediation methods to real-world data to understand how maternal RSVpreF vaccination performs when infant mAb prophylaxis is also used. The abstract does not present estimates, sensitivity analyses, or detailed methods for controlling confounding and selection bias inherent to observational data; those methodological specifics were not reported in the source abstract. Final results, interpretation, and implications for clinical practice will depend on the forthcoming analyses and peer review.
CAUSAL-RSV proposes to use the OLDW national mother–infant cohort to model maternal RSVpreF vaccine effectiveness across three RSV seasons (2023–26) while explicitly accounting for infant long-acting monoclonal antibody receipt as a mediator. The objective is to estimate the total effect of maternal vaccination within hybrid prevention programs. The work is funded by NIAID, disclosed author conflicts are listed, and the protocol has been posted as a medRxiv preprint; no peer review or outcome data are reported in the abstract.